Last updated: 11/06/2018 23:59:34
Study to look at and compare how inhaled and intravenous fluticasone furoate and GW642444 are processed by the body in healthy subjects
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: An open-label, non-randomised, three-way crossover, single dose study to determine the absolute bioavailability of fluticasone furoate (FF)/GW642444 Inhalation Powder, in healthy subjects
Trial description: This study is being done to look at the absolute bioavailability of fluticasone furoate and GW642444 inhalation powder when administered in healthy subjects. Bioavailability is determined by measuring the amount of the dose of inhaled medication that reaches the circulation; the amount of inhaled fluticasone furoate and GW642444 powder will be compared to the medication administered intravenously (where bioavailability is 100%).
Primary purpose:
Other
Trial design:
Crossover Assignment
Masking:
None (Open Label)
Allocation:
Non-randomized
Primary outcomes:
Absolute bioavailability of FF and GW642444 following single dose of FF/GW642444M Inhalation Powder; determined by measuring the amount of the dose of inhaled medication that reaches the circulation compared to the medication administered intravenously
Timeframe: Up to 48hr PK sampling periods profiles on 3 separate occasions over a total period of up to 5 weeks
Secondary outcomes:
Pharmacokinetic parameters: AUC, Cmax, t1/2, tmax, and MRT for all treatments. In addition, volume of distribution (V) and plasma clearance (CL) for intravenous administrations and mean absorption time (MAT) for inhaled treatments
Timeframe: Up to 48hr PK sampling periods profiles on 3 separate occasions over a total period of up to 5 weeks
Number of Participants with clinically significant changes to Vital Signs as a measure of Safety and Tolerability
Timeframe: Approximately 9 weeks for each subject
Number of Participants with clinically significant changes to 12-lead ECG Tests as a measure of Safety and Tolerability
Timeframe: Approximately 9 weeks for each subject
Number of Participants with clinically significant changes to Clinical Laboratory Tests as a measure of Safety and Tolerability
Timeframe: Approximately 9 weeks for each subject
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Timeframe: Approximately 9 weeks for each subject
Interventions:
Enrollment:
16
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Allen A, Apoux L, Bal J, Bianco J, Moore A, Ramiya R, Tombs L, Kempsford RD. The pharmacokinetics of fluticasone furoate (FF) and vilanterol (VI) trifenatate following single inhaled administration in combination and intravenous administration of individual components in healthy subjects. J Bioequiv Availab. 2013;5(4):165-73.
Medical condition
Asthma
Product
fluticasone furoate, vilanterol
Collaborators
GSK
Study date(s)
May 2010 to July 2010
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
18 - 64 years
Accepts healthy volunteers
Yes
- Healthy male or female between 18 and 64 years of age inclusive
- Body mass index (BMI) within the range 18.5-29 0 kg/m2 (inclusive)
- As a result of medical interview, physical examination or screening investigations, the principal investigator or delegate physician deems the subject unsuitable for the study. Subjects must not have a systolic blood pressure above 145 mmHg or a diastolic pressure above 85 mmHg
- Any history of breathing problems in adult life
Inclusion and exclusion criteria
Inclusion criteria:
- Healthy male or female between 18 and 64 years of age inclusive
- Body mass index (BMI) within the range 18.5-29 0 kg/m2 (inclusive)
- Subjects who are current non-smokers
- AST, ALT, alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
- QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block, based on a single ECG value, or an average from three ECGs obtained over a brief recording period
- No significant abnormality on the Holter ECG at screening
- FEV1 ≥ 85% predicted at screening.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
- Subjects who are able to use the inhalation device satisfactorily
Exclusion criteria:
- As a result of medical interview, physical examination or screening investigations, the principal investigator or delegate physician deems the subject unsuitable for the study. Subjects must not have a systolic blood pressure above 145 mmHg or a diastolic pressure above 85 mmHg
- Any history of breathing problems in adult life
- Pregnant or lactating females
- The subject has been treated for or diagnosed with depression within six months of screening or has a history of significant psychiatric illness
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
- Subjects who have suffered a lower respiratory tract infection within 4 weeks of the screening visit
- Subjects with recent history (within 6 months) of pneumonia
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation
- Any adverse reaction including immediate or delayed hypersensitivity to any beta2-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy. Known or suspected sensitivity to the constituents of the new powder inhaler (i.e., lactose or magnesium stearate)
- History of milk protein allergy
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John’s Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety
- The subject has taken oral corticosteroids less than 8 weeks before the screening visit
- The subject has taken inhaled, intranasal or topical steroids less than 4 weeks before the screening visit
- History of alcohol/drug abuse or dependence within 12 months of the study
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- The subject has tested positive for HIV antibodies
- A positive pre-study urine drug screen or when randomly tested during the study
- Positive carbon monoxide (CO) or alcohol breath test at screening or on admission to the Unit.
- Positive urine cotinine test at screening
- Consumption of seville oranges, pomelos (members of the grapefruit family) or grapefruit juice from 7 days prior to the first dose of study medication
- Unwillingness or inability to follow the procedures outlined in the protocol
- Subject is mentally or legally incapacitated
Trial location(s)
Location
GSK Investigational Site
Randwick, New South Wales, Australia, 2031
Status
Study Complete
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2010-15-07
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Results for study 102934 can be found on the GSK Clinical Study Register.
Click hereResearchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website